ClearSight Announces Sale of Parent Company, Sharklet Technologies

Monday, May 22, 2017

AURORA, Colo.--(BUSINESS WIRE)--ClearSight LLC is pleased to announce the acquisition of its parent company Sharklet Technologies, Inc., by Peaceful Union, an equity medical device firm in Hangzhou, China. ClearSight LLC was co-founded by Drs. Kevin Cuevas and Shravanthi Reddy to develop the next generation intraocular lens (IOL) implant. 

New Study Shows Advanced Diagnostic Tests, Including the VeriStrat® Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients

Monday, May 22, 2017

Biodesix’s VeriStrat® Test Is Cost Saving, Can Help Optimize End-of-Life Care

Continue Reading

miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting

Wednesday, May 17, 2017

New Phase 1 data will be released including safety, efficacy and pharmacokinetics after intravenous and subcutaneous administration in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) 

Ventria Bioscience announces peer-reviewed publication on novel mechanism of action in inflammatory bowel disease

Wednesday, May 17, 2017

Collaboration with Children’s Hospital Colorado finds Ventria’s recombinant human lactoferrin modulates immune response 

Sharklet Technologies Announces Acquisition by Peaceful Union and New Partnership to Accelerate Development of Medical Devices and Surface Technologies Featuring Sharklet®

Tuesday, May 16, 2017

AURORA, COLO. – Sharklet Technologies, Inc., a biotechnology company lauded for the creation and commercialization of Sharklet®, the world’s first micro-texture that inhibits bacterial growth on surfaces, today announced that it has completed a financing event led by Peaceful Union, an equity medical device firm in Hangzhou, China. Terms of the transaction were not disclosed. 

Flagship Biosciences to demonstrate how its Computational Tissue Analysis platform advances clinical pipeline development at the Annual Meeting of the American Society of Clinical Oncology

Monday, May 15, 2017

Visit ASCO booth 25115 to learn more about Flagship’s decision support solutions.  

PharmaJet receives 2017 Innovation Award in Biosciences

Thursday, May 11, 2017

GOLDEN, Colo. – May 11, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, announced today that it received the 2017 Innovation Award in Biosciences. The award, part of the Colorado Manufacturing Awards, recognized the company for their innovation in manufacturing and teamwork, particularly in their participation in the effort to eradicate Polio. 

Pathways Bioscience Announces National Institutes of Health NIDCR SBIR Phase I Award to Develop Potential Oral Mucositis Treatment by Nrf2 Activation

Tuesday, May 09, 2017

Pathways Bioscience, LLC announced today that the National Institute of Dental and Craniofacial Research (NIDCR) has awarded the Company a Small Business Innovation Research (SBIR) Phase I grant to pursue research and development of its PB201 topical formulation for use against oral mucositis, a common cancer therapy side effect that impacts hundreds of thousands of patients in the US each year. PB201 activates the Nuclear Factor, Erythroid 2 Like 2 (NFE2L2, also known as Nrf2) transcription factor pathway, which regulates the expression of a large group of cell protective and anti-inflammatory genes. 

Cetya Therapeutics Announces Seed Round Financing

Monday, May 08, 2017

$220,000 Round includes Canadian firm InSynchrony Ventures Inc Proceeds will advance oncology drug development 

Array BioPharma enters clinical trial collaboration with Merck to evaluate drug combo for colorectal cancer

Monday, May 08, 2017

Array BioPharma and Merck agreed to carry out a clinical trial combining Array’s oral MEK inhibitor binimetinib with Merck’s anti-programmed cell death protein 1 (anti-PD-1) therapy Keytruda®(pembrolizumab) in patients with metastatic colorectal cancer (CRC) with microsatellite stable tumors (MSS CRC). The proposed Merck-sponsored trial, which is projected to start during the second half of 2017, will be designed to establish dosing for the combination therapy, as well as explore the potential antitumor activity of a number of treatment regimens. No financial details were disclosed. 

Regional News